Development and validation of a nomogram for evaluating the prognosis of immunotherapy plus antiangiogenic therapy in non-small cell lung cancer.

Huang, Hao; Chen, Yao; Weng, Xuezi; Li, Sirou; Zhang, Lin; Chen, Peisong

Huang, Hao; Chen, Yao; Weng, Xuezi; Li, Sirou; Zhang, Lin; Chen, Peisong.

Afiliação

Huang H; Department of Laboratory Medicine, the First Affiliated Hospital of Sun Yat-Son University, Guangzhou, 510000, Guangdong, China.
Chen Y; Department of Laboratory Medicine, the First Affiliated Hospital of Sun Yat-Son University, Guangzhou, 510000, Guangdong, China.
Weng X; Department of Laboratory Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510000, Guangdong, China.
Li S; Department of Laboratory Medicine, the First Affiliated Hospital of Sun Yat-Son University, Guangzhou, 510000, Guangdong, China.
Zhang L; Department of Laboratory Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510000, Guangdong, China. zhanglin@sysucc.org.cn.
Chen P; Department of Laboratory Medicine, the First Affiliated Hospital of Sun Yat-Son University, Guangzhou, 510000, Guangdong, China. chps@mail3.sysu.edu.cn.

Cancer Cell Int ; 22(1): 261, 2022 Aug 21.

Article em En | MEDLINE | ID: mdl-35989349

Palavras-chave

Antiangiogenic; Immune checkpoint inhibitors; Nomogram; Non-small cell lung cancer; Prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Cancer Cell Int Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google